<DOC>
	<DOCNO>NCT02781766</DOCNO>
	<brief_summary>Haemophilic arthropathy one major complication severe haemophilia . In order maintain plasma clot factor activity level 1 % avoid spontaneous joint bleeds serious bleed event , prophylactic factor replacement therapy use . Because high cost limited availability clot factor concentrate , dose crucial issue prophylaxis therapy . Several study report good correlation clinical bleeding tendency patient haemophilia thrombin generation assay result compare FVIII/FIX level . However specific data show thrombin generation may better indicator clinical efficacy prophylaxis compare conventional FVIII measurement . The main objective open , multicentre , prospective study compare trough thrombin generation capacity FVIII level severe haemophilia patient compare two laboratory result : - number spontaneous haemarthroses spontaneous serious bleeds occur last 6 month - number additional FVIII unit use last 6 month This project require change term type treatment : During study , patient treat usual clotting factor usual regimen ( frequency dosage ) . The clinical outcome usual prophylaxis regimen correlate TGA result</brief_summary>
	<brief_title>TGA ( Thrombin Generation Assay ) Prophylaxis Haemophilia</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe haemophilia A ( FVIII &lt; 1 IU/dl ) Currently prophylactic therapy The prophylaxis regimen last six month Age : 2 ( body weight â‰¥12.5 kg ) 45 year Adequate venous access Haemophilia patient 's diary equivalent regularly complete Ability patient family ( minor ) give inform consent Subject health insurance Age &lt; 2 &gt; 45 year Haemophilia A documented inhibitor last 12 month Clinically symptomatic liver disease ( historical evidence document patient 's medical file ) Platelet count &lt; 100x109/l Poor venous access Presence document target joint Subject legal protection measure .</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Haemophilia A</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>thrombin generation assay</keyword>
	<keyword>factor VIII</keyword>
	<keyword>prophylactic therapy</keyword>
</DOC>